Table 2.

Pooled relative risk of all grade and high grade irAEs for nivolumab vs chemotherapy

All grade irAEs	No. of trials	Pooled RR (95% CI)	Pooled RR	p Value	High grade irAEs	No. of trials	Pooled RR (95% CI)	Pooled RR	p Value
Total incidence	4	0.728–0.805	0.765	0.000	Total incidence	4	0.149–0.324	0.220	0.000
Discontinuation	1	0.454–1.180	0.732	0.200	Discontinuation	1	0.657–2.254	1.217	0.533
Fatigue	4	0.440–0.627	0.525	0.000	Fatigue	4	0.103–0.418	0.208	0.000
Rash	3	0.647–4.516	1.71	0.279	Rash	3	0.248–5.904	1.210	0.814
Nausea	3	0.221–0.534	0.344	0.000	Nausea	3	0.107–1.447	0.394	0.160
Vomiting	1	0.144–0.422	0.246	0.000	Vomiting	1	0.005–1.611	0.090	0.102
Decreased appetite	4	0.345–0.643	0.471	0.000	Decreased appetite	4	0.071–1.387	0.315	0.127
Constipation	1	0.148–0.633	0.306	0.001	Constipation	1	–	–	–
Diarrhea	3	0.231–1.172	0.52	0.115	Diarrhea	3	0.178–1.424	0.504	0.196
Pneumonia	1	0.729–224.957	12.803	0.081	Pneumonia	1	–	–	–
Arthralgia	1	0.294–1.995	0.766	0.585	Arthralgia	1	–	–	–
Neutrophil count decreased	2	0.018–0.111	0.045	0.000	Neutrophil count decreased	2	0.004–0.149	0.025	0.000
Neutropenia	4	0.005–0.144	0.028	0.000	Neutropenia	4	0.005–0.066	0.019	0.000
Anemia	4	0.075–0.161	0.11	0.000	Anemia	4	0.024–0.228	0.075	0.000
Leukopenia	3	0.028–0.435	0.11	0.002	Leukopenia	3	0.012–0.225	0.053	0.000
WBC count decreased	1	0.059–0.225	0.116	0.000	WBC count decreased	1	0.113–0.253	0.169	0.000